For Healthcare Professionals

Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

clipboard-pencil

About the study

This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance and/or uncontrolled systolic hypertension.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Shows lack of cortisol suppression
  2. Suppressed or low early-morning ACTH levels
  3. A radiologically confirmed adrenal lesion
  4. Has IGT or DM
  5. Has uncontrolled hypertension

EXCLUSION CRITERIA

  1. Has severe, uncontrolled hypertension
  2. Has poorly controlled DM
  3. Has DM Type 1
  4. Has significantly abnormal liver test results or severe renal insufficiency
  5. Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 650 327 3270Email iconEmail Study Center

Study’s details


Contition

Hypercortisolism

Age

18+

Phase

Phase 3

Participants needed

130

Est. Completion Date

Jun 2023

Treatment type

Interventional


Sponsor

Corcept Therapeutics

ClinicalTrials.gov identifier

NCT04308590

Study number

CORT125134-456

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.